{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:40:28Z","timestamp":1791168028505,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.drup.2004.03.003","type":"journal-article","created":{"date-parts":[[2004,5,12]],"date-time":"2004-05-12T10:25:44Z","timestamp":1084357544000},"page":"89-95","source":"Crossref","is-referenced-by-count":33,"title":["HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications"],"prefix":"10.1016","volume":"7","author":[{"given":"Michael D","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria J","family":"Hazuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2004.03.003_BIB1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0092-8674(00)81430-0","article-title":"HIV entry and its inhibition","volume":"93","author":"Chan","year":"1998","journal-title":"Cell"},{"issue":"Suppl. 3","key":"10.1016\/j.drup.2004.03.003_BIB2","first-page":"S75","article-title":"HIV viral dynamics","volume":"10","author":"Coffin","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.drup.2004.03.003_BIB3","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"74","author":"Derdeyn","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.drup.2004.03.003_BIB4","doi-asserted-by":"crossref","first-page":"8605","DOI":"10.1128\/JVI.75.18.8605-8614.2001","article-title":"Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"75","author":"Derdeyn","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.drup.2004.03.003_BIB5","first-page":"S106","article-title":"Enfuvirtide (T-20) and T-1249 resistance: observations from Phase II clinical trials of enfuvirtide in combination with oral antiretrovirals and a Phase I\/II dose-ranging monotherapy trial of T-1249","volume":"7","author":"Greenberg","year":"2002","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.drup.2004.03.003_BIB6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1006\/jmbi.2001.4648","article-title":"The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance","volume":"309","author":"Hsiou","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.drup.2004.03.003_BIB7","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/3293","article-title":"Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry [see comments]","volume":"4","author":"Kilby","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2004.03.003_BIB8","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.drup.2004.03.003_BIB9","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1128\/JVI.74.4.1961-1972.2000","article-title":"Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus","volume":"74","author":"Kwong","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.drup.2004.03.003_BIB10","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1073\/pnas.96.9.5215","article-title":"Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages","volume":"96","author":"Lee","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.drup.2004.03.003_BIB11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/367989","article-title":"Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population","volume":"187","author":"Leigh Brown","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.drup.2004.03.003_BIB12","first-page":"S150","article-title":"Low frequency non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant variants contribute to failure of efavirenz-containing regimens in NNRTI-experienced patients with negative standard genotypes for NNRTI mutations","volume":"8","author":"Mellors","year":"2003","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.drup.2004.03.003_BIB13","first-page":"S68","article-title":"CCR5 cell surface density and HIV-1 envelope sequences govern antiretroviral potency of CCR5 antagonists","volume":"8","author":"Miller","year":"2003","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.drup.2004.03.003_BIB14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00126334-200210010-00002","article-title":"Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information","volume":"31","author":"Parkin","year":"2002","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.drup.2004.03.003_BIB15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1128\/AAC.48.2.437-443.2004","article-title":"Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1","volume":"48","author":"Parkin","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2004.03.003_BIB16","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"Petropoulos","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2004.03.003_BIB17","doi-asserted-by":"crossref","first-page":"16249","DOI":"10.1073\/pnas.252469399","article-title":"Sensitivity of HIV-1 to entry inhibitors correlates with envelope\/coreceptor affinity, receptor density, and fusion kinetics","volume":"99","author":"Reeves","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.drup.2004.03.003_BIB18","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.0630530100","article-title":"Rapid evolution of the neutralizing antibody response to HIV type 1 infection","volume":"100","author":"Richman","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.drup.2004.03.003_BIB19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/JVI.72.2.986-993.1998","article-title":"Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides","volume":"72","author":"Rimsky","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.drup.2004.03.003_BIB20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CMR.15.2.247-277.2002","article-title":"Genotypic testing for human immunodeficiency virus type 1 drug resistance","volume":"15","author":"Shafer","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.drup.2004.03.003_BIB21","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1128\/JVI.64.12.5840-5850.1990","article-title":"Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1","volume":"64","author":"Simmonds","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.drup.2004.03.003_BIB22","first-page":"S0","article-title":"Subgroup analysis of baseline susceptibility and early virological response to enfuvirtide in the combined TORO studies","volume":"8","author":"Sista","year":"2003","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.drup.2004.03.003_BIB23","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1007\/PL00000626","article-title":"Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)","volume":"57","author":"Sluis-Cremer","year":"2000","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.drup.2004.03.003_BIB24","first-page":"S59","article-title":"Search for polymorphic sites in R5 tropic HIV-1 Env and enfuvirtide drug susceptibility in baseline isolates from TORO 1 and TORO 2","volume":"8","author":"Su","year":"2003","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.drup.2004.03.003_BIB25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/1568005033481051","article-title":"Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design","volume":"3","author":"Velazquez-Campoy","year":"2003","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"10.1016\/j.drup.2004.03.003_BIB26","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2004.03.003_BIB27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.drup.2004.03.003_BIB28","unstructured":"Whitcomb, J.M., Huang, W., Fransen, S., Wrin, T., Paxinos, E., Toma, J., Greenberg, M., Sista, P., Melby, T., Matthews, T.J., DeMasi, R., Heilek-Snyder, G., Cammack, N., Hellmann, N., Petropoulos, C.J. (2003). Analysis of baseline enfuvirtide (T20) susceptibility and co-receptor tropism in two phase III study populations. In: Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections, February 10\u201314, 2003, Boston, MA."},{"key":"10.1016\/j.drup.2004.03.003_BIB29","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1126\/science.280.5371.1884","article-title":"The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens","volume":"280","author":"Wyatt","year":"1998","journal-title":"Science"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764604000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764604000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T03:59:32Z","timestamp":1585799972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764604000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S1368764604000263"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2004.03.003","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}